Literature DB >> 20503361

Embryonic and not maternal trisomy causes developmental attenuation in the Ts65Dn mouse model for Down syndrome.

Joshua D Blazek1, Cherie N Billingsley, Abby Newbauer, Randall J Roper.   

Abstract

Trisomy 21 results in Down syndrome (DS) and causes phenotypes that may result from alterations of developmental processes. The Ts65Dn mouse is the most widely used genetic and phenotypic model for DS. We used over 1,500 offspring from Ts65Dn and two nontrisomic genetically similar control strains to investigate the influence of trisomy on developmental alterations and number of offspring. For the first time, we demonstrate gross developmental attenuation of Ts65Dn trisomic offspring at embryonic day (E) 9.5 and E13.5 and show that the major determinant of the developmental changes is segmental trisomy of the embryo and not the trisomic maternal uterine environment. Maternal alleles of nontrisomic genes linked to Pde6b may also influence the development of Ts65Dn offspring. Both developmental attenuation and the contribution of trisomic and nontrisomic genes are important components in the genesis of DS phenotypes.

Entities:  

Mesh:

Year:  2010        PMID: 20503361     DOI: 10.1002/dvdy.22295

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  11 in total

1.  Trisomic and allelic differences influence phenotypic variability during development of Down syndrome mice.

Authors:  Samantha L Deitz; Randall J Roper
Journal:  Genetics       Date:  2011-09-16       Impact factor: 4.562

2.  Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.

Authors:  Samantha D McElyea; John M Starbuck; Danika M Tumbleson-Brink; Emily Harrington; Joshua D Blazek; Ahmed Ghoneima; Katherine Kula; Randall J Roper
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

3.  Down syndrome mouse models have an abnormal enteric nervous system.

Authors:  Ellen M Schill; Christina M Wright; Alisha Jamil; Jonathan M LaCombe; Randall J Roper; Robert O Heuckeroth
Journal:  JCI Insight       Date:  2019-04-18

4.  Commonality in Down and fetal alcohol syndromes.

Authors:  Jeffrey P Solzak; Yun Liang; Feng C Zhou; Randall J Roper
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-04-03

5.  Trisomy 21 and facial developmental instability.

Authors:  John M Starbuck; Theodore M Cole; Roger H Reeves; Joan T Richtsmeier
Journal:  Am J Phys Anthropol       Date:  2013-03-15       Impact factor: 2.868

Review 6.  Skeletal dynamics of Down syndrome: A developing perspective.

Authors:  Jonathan M LaCombe; Randall J Roper
Journal:  Bone       Date:  2019-12-27       Impact factor: 4.398

7.  Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome.

Authors:  Cherie N Billingsley; Jared R Allen; Douglas D Baumann; Samantha L Deitz; Joshua D Blazek; Abby Newbauer; Andrew Darrah; Brad C Long; Brandon Young; Mark Clement; R W Doerge; Randall J Roper
Journal:  Am J Med Genet A       Date:  2013-07-10       Impact factor: 2.802

8.  Novel insights from fetal and placental phenotyping in 3 mouse models of Down syndrome.

Authors:  April D Adams; Victoria Hoffmann; Laura Koehly; Faycal Guedj; Diana W Bianchi
Journal:  Am J Obstet Gynecol       Date:  2021-03-22       Impact factor: 10.693

9.  Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration.

Authors:  Jaeryung Kim; Jang Ryul Park; Jeongwoon Choi; Intae Park; Yoonha Hwang; Hosung Bae; Yongjoo Kim; WooJhon Choi; Jee Myung Yang; Sangyeul Han; Tae-Young Chung; Pilhan Kim; Yoshiaki Kubota; Hellmut G Augustin; Wang-Yuhl Oh; Gou Young Koh
Journal:  Sci Adv       Date:  2019-02-13       Impact factor: 14.136

10.  Retinal degeneration mutation in Sftpa1tm1Kor/J and Sftpd -/- targeted mice.

Authors:  Faizah Bhatti; Johannes W Kung; Frederico Vieira
Journal:  PLoS One       Date:  2018-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.